bioMETRX, Inc. Rated 'Speculative Buy,' Target $4.67 by Beacon Equity Research

Business Wire, May 8, 2006

DALLAS -- bioMETRX, Inc. (OTCBB:BMRX) has been rated "Speculative Buy," with a price target of $4.67 by Beacon Equity Research. The report is authored by Senior Research Analyst, Michael Schmidt, CFA.

The full report is available at http://www.beaconequityresearch.com.

In the report Mr. Schmidt writes, "Identix (Nasdaq: IDNX), Viisage (Nasdaq: VISG), are among the major players in the facial recognition segment. While only a few operators such as Cogent Systems (Nasdaq: COGT) and Safelink Corp. (Nasdaq: SFLK) compete in the IP-intense fingerprint environment, a number of vendors compete in the component technology segment.

"bioMETRX products utilize fingerprint recognition technology designed to enhance or replace conventional security methods such as keys, keypads and PIN numbers. The Company is now passing the development stage and intends to become the first company to have a biometric consumer electronics product available in the market. The Company primarily focuses on the consumer/small business electronics markets. It conducts testing and quality control checks at all levels to deliver quality products backed by warranties and attentive after-sales service."

Beacon Equity Research Disclosure

The analysts contributing to this report do not hold any shares of bioMETRX, Inc. (BMRX). Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. The analyst(s) writing this report recognize and aspire to all of the CFA Institute Guidelines for Independent Research. Beacon Equity Research ("Beacon") certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analysts in the report. A principal of Beacon Equity Research is also a principal of Pasadena Capital Partners, an investor relations firm for BMRX which has received 20,000 restricted rule 144 shares directly from BMRX for services. Beacon expects to receive $18,000 from BMRX for a one-year enrollment in its research program. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change.

Anyone interested in receiving alerts regarding bioMETRX, Inc. research should email members@beaconequityresearch.com with "BMRX" in the subject line.